🔎 Today’s Daily Sift: Longevity The longevity industry just crossed a historic threshold. For the first time, a cellular rejuvenation therapy has been injected into a human. For years, longevity was dominated by supplements, wearables, diagnostics, and optimization culture. Today marks a transition from wellness to biotechnology. Life Biosciences has dosed the first patient with ER100, a therapy designed to restore youthful function to damaged optic nerve cells using partial epigenetic reprogramming. This approach is based on the same biological principles behind Yamanaka factor research that previously demonstrated rejuvenation effects in animal studies. The implications extend far beyond eyesight. If successful, the same framework could eventually be adapted to treat multiple age related conditions by restoring cellular function rather than simply managing symptoms. The market is entering a new phase where human data matters more than laboratory promises. Investors are incr...